IL275498B2 - Heavy chain antibodies that bind CD22 - Google Patents

Heavy chain antibodies that bind CD22

Info

Publication number
IL275498B2
IL275498B2 IL275498A IL27549820A IL275498B2 IL 275498 B2 IL275498 B2 IL 275498B2 IL 275498 A IL275498 A IL 275498A IL 27549820 A IL27549820 A IL 27549820A IL 275498 B2 IL275498 B2 IL 275498B2
Authority
IL
Israel
Prior art keywords
heavy chain
antibody
seq
sequence
antibodies
Prior art date
Application number
IL275498A
Other languages
English (en)
Hebrew (he)
Other versions
IL275498A (en
IL275498B1 (en
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of IL275498A publication Critical patent/IL275498A/en
Publication of IL275498B1 publication Critical patent/IL275498B1/en
Publication of IL275498B2 publication Critical patent/IL275498B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL275498A 2017-12-22 2018-12-21 Heavy chain antibodies that bind CD22 IL275498B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762609759P 2017-12-22 2017-12-22
PCT/US2018/067299 WO2019126756A1 (en) 2017-12-22 2018-12-21 Heavy chain antibodies binding to cd22

Publications (3)

Publication Number Publication Date
IL275498A IL275498A (en) 2020-08-31
IL275498B1 IL275498B1 (en) 2026-01-01
IL275498B2 true IL275498B2 (en) 2026-05-01

Family

ID=65041936

Family Applications (1)

Application Number Title Priority Date Filing Date
IL275498A IL275498B2 (en) 2017-12-22 2018-12-21 Heavy chain antibodies that bind CD22

Country Status (24)

Country Link
US (2) US11873336B2 (cg-RX-API-DMAC7.html)
EP (1) EP3728319A1 (cg-RX-API-DMAC7.html)
JP (2) JP7486421B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250093583A (cg-RX-API-DMAC7.html)
CN (1) CN111683966B (cg-RX-API-DMAC7.html)
AU (1) AU2018392088A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020012554A2 (cg-RX-API-DMAC7.html)
CA (1) CA3086665A1 (cg-RX-API-DMAC7.html)
CL (3) CL2020001703A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020008925A2 (cg-RX-API-DMAC7.html)
CR (1) CR20200322A (cg-RX-API-DMAC7.html)
EA (1) EA202091557A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP20042489A (cg-RX-API-DMAC7.html)
IL (1) IL275498B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20200157B1 (cg-RX-API-DMAC7.html)
MX (1) MX2020006494A (cg-RX-API-DMAC7.html)
MY (1) MY204744A (cg-RX-API-DMAC7.html)
NI (1) NI202000050A (cg-RX-API-DMAC7.html)
PE (1) PE20201171A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020550964A1 (cg-RX-API-DMAC7.html)
SA (1) SA520412283B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202005880XA (cg-RX-API-DMAC7.html)
UA (1) UA128757C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019126756A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン, インコーポレイテッド 抗bcma重鎖のみ抗体
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
WO2021188599A1 (en) 2020-03-16 2021-09-23 University Of Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
KR20210143097A (ko) * 2020-05-19 2021-11-26 (주)이노베이션바이오 Cd22에 특이적인 항체 및 이의 용도
US20230250184A1 (en) * 2020-07-16 2023-08-10 Nanjing Legend Biotech Co., Ltd. Cd22 binding molecules and uses thereof
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Cd20結合分子及びその使用
MX2023009882A (es) * 2021-02-26 2023-08-30 Teneobio Inc Anticuerpos anti-muc1-c y estructuras car-t.
CN121969385A (zh) 2023-09-11 2026-05-01 丹娜-法伯癌症研究院 含有il-2变体以增强car t细胞的功能性的car-衔接子

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170174770A1 (en) * 2012-12-14 2017-06-22 Ligand Pharmaceuticals, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
US20170275363A1 (en) * 2014-02-25 2017-09-28 Immunomedics, Inc. Humanized anti-cd22 antibody

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
WO2010032061A1 (en) 2008-09-19 2010-03-25 Medimmune Llc Antibodies against sonic hedgehog homolog and uses thereof
MX2011003502A (es) 2008-10-01 2011-09-01 Micromet Ag Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究(慕尼黑)有限責任公司 跨物種專一性之PSMAxCD3雙專一性單鏈抗體
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
CN103619876A (zh) 2011-03-10 2014-03-05 Hco抗体股份有限公司 双特异性三链抗体样分子
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
IN2014MN02293A (cg-RX-API-DMAC7.html) 2012-04-20 2015-08-07 Emergent Product Dev Seattle
JP2015516984A (ja) 2012-04-26 2015-06-18 バイオアトラ、エルエルシー 抗cd22抗体
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Bcmaに対する抗体の選択のための方法
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
EP3105252B1 (en) 2014-02-12 2019-07-24 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
ES2808853T3 (es) 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
CN104710528B (zh) * 2015-03-13 2019-02-15 西北农林科技大学 一种特异性结合PRRS病毒非结构蛋白Nsp9纳米抗体及其应用
UA126657C2 (uk) 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CN109862784A (zh) * 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン, インコーポレイテッド 抗bcma重鎖のみ抗体
WO2019006072A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CHIMERIC ANTIGENIC RECEPTORS TO ANTIGEN OF MATURATION OF LYMPHOCYTES B WITH HUMAN DOMAINS
US20200207867A1 (en) 2017-09-13 2020-07-02 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
EP3732199A1 (en) 2017-12-27 2020-11-04 TeneoBio, Inc. Cd3-delta/epsilon heterodimer specific antibodies
LT3823990T (lt) 2018-07-20 2026-04-10 TeneoTwo, Inc. Antikūnai iš sunkiosios grandinės, besirišantys prie cd19
SG11202102713TA (en) 2018-09-21 2021-04-29 Teneobio Inc Methods for purifying heterodimeric, multispecific antibodies
WO2020087065A1 (en) 2018-10-26 2020-04-30 Teneobio, Inc. Heavy chain antibodies binding to cd38
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
BR112022011824A2 (pt) 2019-12-18 2022-08-30 Teneofour Inc Anticorpos de cadeia pesada que se ligam a cd38
WO2021222616A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Methods of treating multiple myeloma
KR20250007022A (ko) 2020-04-29 2025-01-13 테네오원, 인코포레이티드 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
IL299027A (en) 2020-06-30 2023-02-01 Teneobio Inc Multispecific antibodies that bind BCMA
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
WO2022183074A2 (en) 2021-02-25 2022-09-01 Teneobio, Inc. Anti-psma antibodies and car-t structures
MX2023009882A (es) 2021-02-26 2023-08-30 Teneobio Inc Anticuerpos anti-muc1-c y estructuras car-t.
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗il-2r抗體及使用方法
PE20260568A1 (es) 2021-04-06 2026-03-10 Teneobio Inc Anticuerpos anti-cd19 y estructuras car-t
CN117337303A (zh) 2021-04-16 2024-01-02 特尼奥生物股份有限公司 抗cd20抗体及car-t结构
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170174770A1 (en) * 2012-12-14 2017-06-22 Ligand Pharmaceuticals, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
US20170275363A1 (en) * 2014-02-25 2017-09-28 Immunomedics, Inc. Humanized anti-cd22 antibody

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AGHA AMIRI, SOLMAZ, ET AL., A NOVEL ANTI-CD22 SCFV–APOPTIN FUSION PROTEIN INDUCES APOPTOSIS IN MALIGNANT B-CELLS., 2 June 2017 (2017-06-02) *
BUELOW, BEN, ET AL., DEVELOPMENT OF A FULLY HUMAN T CELL ENGAGING BISPECIFIC ANTIBODY FOR THE TREATMENT OF MULTIPLE MYELOMA., 30 May 2017 (2017-05-30) *
JANSSENS, RICK, ET AL., GENERATION OF HEAVY-CHAIN-ONLY ANTIBODIES IN MICE., 10 October 2006 (2006-10-10) *
LEOW, CHIUAN HERNG, ET AL., SINGLE DOMAIN ANTIBODIES AS NEW BIOMARKER DETECTORS., 17 October 2017 (2017-10-17) *
TRINKLEIN, NATHAN, ET AL., ABSTRACT LB-090: SEQUENCE-BASED DISCOVERY OF FULLY HUMAN ANTI-CD3 AND ANTI-PDL1 SINGLE DOMAIN ANTIBODIES USING NOVEL TRANSGENIC RATS., 15 July 2016 (2016-07-15) *
ZAREI, NAJMEH, ET AL., HIGH EFFICIENT EXPRESSION OF A FUNCTIONAL HUMANIZED SINGLE-CHAIN VARIABLE FRAGMENT (SCFV) ANTIBODY AGAINST CD22 IN PICHIA PASTORIS., 21 September 2014 (2014-09-21) *

Also Published As

Publication number Publication date
UA128757C2 (uk) 2024-10-16
CO2020008925A2 (es) 2020-10-30
CN111683966B (zh) 2023-07-11
US20210095022A1 (en) 2021-04-01
WO2019126756A9 (en) 2019-10-17
EP3728319A1 (en) 2020-10-28
SA520412283B1 (ar) 2024-08-05
JP7486421B2 (ja) 2024-05-17
JOP20200157B1 (ar) 2024-12-22
MY204744A (en) 2024-09-11
CL2024002319A1 (es) 2024-12-06
CN111683966A (zh) 2020-09-18
KR102823263B1 (ko) 2025-06-24
KR20200104342A (ko) 2020-09-03
JOP20200157A1 (ar) 2022-10-30
JP2021506325A (ja) 2021-02-22
SG11202005880XA (en) 2020-07-29
BR112020012554A2 (pt) 2020-11-24
AU2018392088A1 (en) 2020-08-13
CL2022002247A1 (es) 2023-02-24
IL275498A (en) 2020-08-31
EA202091557A1 (ru) 2020-11-18
US20240117046A1 (en) 2024-04-11
MX2020006494A (es) 2020-11-24
PE20201171A1 (es) 2020-10-28
WO2019126756A1 (en) 2019-06-27
JP2024062992A (ja) 2024-05-10
AU2018392088A2 (en) 2020-08-27
CR20200322A (es) 2021-01-12
NI202000050A (es) 2020-12-04
IL275498B1 (en) 2026-01-01
JP7891025B2 (ja) 2026-07-15
PH12020550964A1 (en) 2021-03-22
CL2020001703A1 (es) 2020-11-06
ECSP20042489A (es) 2020-11-30
KR20250093583A (ko) 2025-06-24
US11873336B2 (en) 2024-01-16
RU2020124188A (ru) 2022-01-24
CA3086665A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
IL275498A (en) Heavy chain antibodies that bind CD22
IL279010B1 (en) Heavy chain antibodies that bind to CD19
IL276537A (en) Antibodies bind to GPRC5D
IL287613A (en) Antibodies that bind gprc5d
IL274370A (en) Single-region antibodies that bind CD137
IL286398A (en) Heavy chain antibodies that bind to psma
ZA201801427B (en) Antibodies that specifically bind to tl1a
ZA201905341B (en) Antibodies specifically binding to human il-1r7
IL312322B2 (en) Antibodies against BCMA containing only heavy chains
IL261188A (en) Antibodies against tigit
ZA201803669B (en) Antibodies specifically binding pd-1 and their uses
IL256846A (en) antibody molecules that bind cd22
IL269394A (en) Antibodies bind to STEAP-1
IL282590A (en) Heavy chain antibodies that bind to CD38
IL273235A (en) Heavy chain antibodies that bind to ectoenzymes
IL271128A (en) New anti-3cd antibodies
ZA202103456B (en) Anti-alpha-synuclein antibodies
HUE051165T2 (hu) ANG-2 elleni, csak nehézláncot tartalmazó antitestek
SI3452515T1 (sl) Protitelesa, ki se vežejo na her-2
GB201709379D0 (en) Humanised ADAMTS13 binding antibodies
HK40039228A (en) Heavy chain antibodies binding to cd22
HK40034161A (en) Heavy chain antibodies binding to ectoenzymes
HK40056602A (en) Heavy chain antibodies binding to cd38
GB201715149D0 (en) IL-ß binding antibody
GB201718734D0 (en) Single domain antibodies that bind to CD137